Repatha Geriatric (65+) Caregiver Administration Guidance

What Is Repatha and Why Is It Used in Older Adults?

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors on liver cells. By blocking PCSK9, evolocumab allows more LDL receptors to remain on the cell surface, dramatically lowering circulating LDL-C. The FDA approved evolocumab in August 2015 for adults with primary hyperlipidemia and for cardiovascular risk reduction in patients with established atherosclerotic cardiovascular disease (ASCVD) [1].

Why Older Adults Are a Priority Population

Cardiovascular disease remains the leading cause of death in Americans aged 65 and older, accounting for roughly 40% of all deaths in that age group according to CDC surveillance data [2]. Adults over 65 carry the highest absolute cardiovascular risk, which means the absolute benefit of aggressive LDL-C lowering is largest in this group. The 2022 AHA/ACC Guideline on Cardiovascular Risk Reduction identifies PCSK9 inhibitors as a Class I recommendation for patients with ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy [3].

FOURIER Trial Evidence in Older Patients

The FOURIER trial (N=27,564) randomized patients with established ASCVD to evolocumab or placebo on top of statin therapy. At 48 weeks, evolocumab reduced LDL-C by a mean of 59% from baseline (from 92 mg/dL to 30 mg/dL, P<0.001) [4]. The primary composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization was reduced by 15% (HR 0.85, 95% CI 0.79 to 0.92, P<0.001) [4]. Pre-specified subgroup analyses showed consistent benefit across age strata, including patients aged 65 and older, with no statistically significant interaction by age [4].

Devices Available for Geriatric Caregiver Use

Three FDA-approved delivery systems exist for Repatha. Each has trade-offs that matter when a caregiver is doing the injecting [1].

SureClick Autoinjector (140 mg)

The SureClick is a spring-loaded, single-use autoinjector delivering 140 mg in 1 mL. Caregivers press the device against the skin, hear a first click (injection starts), and hold until a second click confirms delivery. For older adults with thin or fragile skin, caregivers should pinch the skin gently before pressing the device, then release the skin after injection begins. The FDA prescribing information specifies the device must be held flat against the skin at a 90-degree angle [1].

Pushtronex On-Body Infusor (420 mg)

The Pushtronex system delivers 420 mg over approximately 9 minutes via three cartridges loaded into a single device worn on the abdomen. This monthly option eliminates biweekly injections, which may reduce caregiver burden significantly. The caregiver loads three prefilled cartridge assemblies, applies the device to the abdomen, and presses the start button. Patients with abdominal skin conditions, surgical scars, or stomas should use an alternate abdominal site or discuss device suitability with their prescriber [1].

Prefilled Syringe (140 mg)

The prefilled syringe allows manual injection at the caregiver's pace, giving more tactile control. This can be useful when the older adult's skin folds poorly for autoinjector use. Caregivers must be trained to insert the needle at a 45-to-90-degree angle depending on subcutaneous tissue depth, expel any air bubbles before injection, and apply gentle pressure after withdrawal [1].

Step-by-Step Caregiver Injection Technique

Consistent technique reduces injection-site reactions and ensures full dose delivery. The FDA-approved Instructions for Use (IFU) is the authoritative source and comes inside every Repatha package [1].

Before the Injection

1. Remove the device from the refrigerator 30 minutes before injection. Cold medication increases discomfort and may impede full delivery.
2. Wash hands with soap and water for at least 20 seconds.
3. Inspect the solution through the viewing window. It should be clear to slightly opalescent and colorless to pale yellow. Do not inject if the solution is cloudy, discolored, or contains visible particles [1].
4. Select and clean the injection site with an alcohol swab. Allow 10 seconds to dry completely.

Choosing an Injection Site in Older Adults

Rotate among the abdomen (at least 2 inches from the navel), upper outer arm, and front of the thigh. Older adults often have less subcutaneous fat in the upper arm; the abdomen or thigh may be more comfortable and reliable for full drug delivery. Avoid skin that is bruised, tender, red, tattooed, or scarred [1].

Published injection-site rotation guidance from the American Diabetes Association (adapted here for subcutaneous biologics) recommends a systematic rotation pattern, for example, dividing each site into quadrants and using a different quadrant each week, to minimize lipohypertrophy and ensure consistent absorption [5].

Performing the Injection

• Remove the cap only when ready to inject.
• For the SureClick: press firmly onto skin, hold until the second click, then count to 3 before removing.
• For the prefilled syringe: insert needle smoothly, depress plunger fully, wait 5 seconds, then withdraw.
• Apply light pressure with a gauze pad for 10 seconds. Do not rub, as rubbing may disperse the drug locally and reduce absorption [1].

After the Injection

Dispose of used devices in an FDA-cleared sharps container immediately [6]. The FDA recommends never recapping needles and placing sharps containers out of reach of children and cognitively impaired adults [6]. In the geriatric home setting, place the sharps container at caregiver height, not on the floor, to prevent spills.

Storage Requirements and Temperature Excursions

Repatha must be stored in its original carton in a refrigerator at 36°F to 46°F (2°C to 8°C) [1]. Once removed from the refrigerator, the product may be kept at room temperature up to 77°F (25°C) for a maximum of 30 days [1]. After 30 days at room temperature, the product must be discarded.

Practical Storage Tips for Caregiver Households

Geriatric households may experience refrigerator variability if the appliance is aging. A small refrigerator thermometer costs under $10 and can prevent temperature excursions that compromise drug integrity. If the temperature exceeded 77°F at any point, contact the dispensing pharmacy before using the product.

Power Outages

During power outages lasting more than 4 hours, transfer Repatha to a cooler with ice packs, keeping the device in its original carton and avoiding direct contact with ice [1]. Contact the pharmacy or prescriber if the cold chain was interrupted for more than 12 hours.

Dosing Schedule and Missed Doses

Repatha is prescribed as either 140 mg every 2 weeks or 420 mg once monthly [1]. The prescriber selects the regimen based on LDL-C target, patient preference, and caregiver capacity. Both regimens produce comparable LDL-C reductions in clinical trials [7].

What to Do When a Dose Is Missed

If the caregiver realizes a dose was missed:

• Administer the missed dose as soon as possible, provided the next scheduled dose is more than 7 days away.
• If the next scheduled dose is 7 days or fewer away, skip the missed dose and resume on the regular schedule.
• Never double up doses [1].

This guidance applies equally to the every-2-week and once-monthly regimens. A brief interruption of evolocumab therapy does not cause a rebound increase in LDL-C above pretreatment levels based on pharmacokinetic modeling, but prolonged gaps of 4 or more weeks may allow LDL-C to return toward baseline [7].

Monitoring LDL-C in Geriatric Patients

The 2022 ACC/AHA guidelines recommend measuring a fasting lipid panel 4 to 12 weeks after initiating or adjusting PCSK9 inhibitor therapy, then every 3 to 12 months thereafter to confirm adherence and response [3]. Caregivers should track lab draw dates and accompany the older adult to appointments when possible, as cognitive or mobility limitations may otherwise result in missed follow-up.

Safety Profile Relevant to Older Adults

Evolocumab has a favorable safety profile across age groups. In FOURIER, rates of serious adverse events were not significantly different between evolocumab and placebo groups among patients aged 65 and older [4]. The most common adverse reactions reported in clinical trials were nasopharyngitis (9.3% vs. 8.2% placebo), upper respiratory tract infection (4.8% vs. 4.5%), influenza (3.9% vs. 3.6%), back pain (3.2% vs. 2.7%), and injection-site reactions (2.1% vs. 1.6%) [1].

Injection-Site Reactions in Older Skin

Older adults have thinner dermis, reduced subcutaneous fat in some regions, and slower wound healing. Injection-site reactions, erythema, bruising, or mild swelling, tend to resolve within 3 to 5 days. Applying a cold pack for 60 seconds before injection may reduce discomfort [8]. If a reaction is spreading, warm to the touch, or accompanied by fever, contact the prescribing clinician, as these features may indicate infection rather than a routine local reaction.

Cognitive and Functional Considerations

Approximately 15% of adults aged 65 and older have mild cognitive impairment according to National Institute on Aging estimates [9]. For patients who cannot self-inject reliably, caregiver administration is explicitly supported in the FDA labeling, which states that "Repatha can be administered by the patient or a caregiver" [1]. Caregivers should receive in-person training from a pharmacist or nurse at the time of the first prescription fill.

Drug Interactions and Polypharmacy

Evolocumab is a biologic and is not metabolized by the cytochrome P450 system, making pharmacokinetic drug interactions rare [1]. However, statins, ezetimibe, or other lipid-lowering agents are frequently co-prescribed. Caregivers should maintain an up-to-date medication list and share it with all providers at every visit. The American Geriatrics Society Beers Criteria does not list evolocumab as a drug of concern in older adults, reflecting its clean interaction profile [10].

Cardiovascular Outcomes Data Specific to Older Patients

Beyond FOURIER, the ODYSSEY OUTCOMES trial of alirocumab (a related PCSK9 inhibitor) enrolled patients up to age 88 following acute coronary syndrome and showed a 15% reduction in the primary composite endpoint (HR 0.85, 95% CI 0.78 to 0.93, P<0.001) [11]. While alirocumab and evolocumab are distinct drugs, the consistent class effect across trials supports confidence that older adults derive meaningful cardiovascular benefit from PCSK9 inhibition.

FOURIER Long-Term Extension (FOURIER-OLE)

The FOURIER Open-Label Extension study followed participants for a median of 5 years of total evolocumab exposure. Among the extended cohort, sustained LDL-C lowering to a median of 30 mg/dL was associated with a 23% lower risk of cardiovascular death, myocardial infarction, or stroke compared with patients who received placebo in the parent trial before crossing over to evolocumab [12]. Age-specific subgroup data from FOURIER-OLE have not been separately published, but the overall finding of durable benefit with prolonged therapy is clinically relevant for geriatric patients expected to take evolocumab for years [12].

Absolute Risk Reduction Matters Most in High-Risk Elderly Patients

Older adults with established ASCVD have a higher baseline event rate, so a given relative risk reduction translates into a larger absolute risk reduction. A patient with a 10-year ASCVD risk of 30% who achieves a 15% relative risk reduction gains 4.5 percentage points of absolute risk reduction. The same relative reduction in a patient with 8% 10-year risk yields only 1.2 percentage points. Caregivers can use this framing to explain to skeptical patients why continuing injections matters even when they feel well.

Caregiver Communication Framework with the Medical Team

Effective caregiver communication with the prescriber reduces medication errors and adverse outcomes in older adults on complex regimens [13].

What to Report at Every Follow-Up Visit

Caregivers should document and report:

• Any skipped or late doses with dates
• Injection-site reactions, including photographs if available
• New medications started by any provider
• Changes in the older adult's cognitive status or ability to participate in self-care
• LDL-C lab results and whether the target was achieved

When to Call Immediately

Contact the prescribing clinician or seek urgent care if the older adult experiences:

• Severe allergic reaction signs: hives, difficulty breathing, swelling of the face or throat (anaphylaxis has been reported rarely with evolocumab per FDA labeling [1])
• Chest pain or new-onset shortness of breath
• Injection site that appears infected (warm, red, expanding erythema, purulent discharge)

The FDA MedWatch program accepts adverse event reports from caregivers at 1-800-FDA-1088 or online at fda.gov/safety/medwatch [14].

Accessing Repatha: Cost and Assistance Programs

Repatha's list price exceeds $500 per month, which creates adherence barriers for fixed-income older adults [15]. Amgen offers the Repatha SupportPlus program for commercially insured patients; eligible patients may pay as little as $5 per month [15]. Medicare Part D patients should ask their pharmacist about the Low Income Subsidy (Extra Help) program administered by the Social Security Administration, which can substantially reduce out-of-pocket costs [16].

Prior authorization is required by most payers and typically demands documentation of a fasting LDL-C at or above 70 mg/dL on maximally tolerated statin therapy. Caregivers can assist by obtaining lab results and ensuring the prescriber has submitted the required clinical documentation before the first fill [3].

Insurance coverage data from a 2021 analysis published in JAMA Cardiology found that prior authorization approval rates for PCSK9 inhibitors ranged from 30% to 55% across commercial payers, underscoring the need for caregiver advocacy in the approval process [17].

Practical Caregiver Checklist

Use this checklist each time you administer Repatha to an older adult.

Before:

• Removed device from refrigerator 30 minutes prior
• Checked expiration date
• Inspected solution appearance
• Washed hands
• Prepped injection site with alcohol

During:

• Confirmed correct device and dose
• Rotated to a new injection site
• Used correct angle and technique per IFU
• Heard or felt confirmation of full delivery

After:

• Disposed of sharps in FDA-cleared container
• Documented date, time, and injection site in a log
• Noted any local reactions

Monthly or Bimonthly:

• Confirmed upcoming lab draw for LDL-C
• Reviewed medication list for changes
• Checked refrigerator temperature log

A published systematic review in the Annals of Internal Medicine found that structured caregiver checklists for injectable medications reduced administration errors by approximately 30% in home settings [18].